Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000057498 | SCV000842671 | uncertain significance | not provided | 2018-06-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001854179 | SCV002172437 | pathogenic | Charcot-Marie-Tooth disease type 2 | 2025-01-06 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 33 of the LMNA protein (p.Glu33Asp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of autosomal dominant LMNA-related conditions (PMID: 14985400, 22326558; internal data). ClinVar contains an entry for this variant (Variation ID: 66965). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt LMNA protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Epithelial Biology; Institute of Medical Biology, |
RCV000057498 | SCV000088612 | not provided | not provided | no assertion provided | not provided | ||
Inherited Neuropathy Consortium | RCV000790002 | SCV000929391 | uncertain significance | Charcot-Marie-Tooth disease | no assertion criteria provided | literature only |